These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1911386)

  • 1. Biological significance of cell cycle kinetics in 128 standard risk newly diagnosed patients with acute myelocytic leukemia.
    Raza A; Preisler H; Lampkin B; Yousuf N; Tucker C; Peters N; White M; Kukla C; Gartside P; Siegrist C
    Br J Haematol; 1991 Sep; 79(1):33-9. PubMed ID: 1911386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct relationship between remission duration in acute myeloid leukemia and cell cycle kinetics: a leukemia intergroup study.
    Raza A; Preisler HD; Day R; Yasin Z; White M; Lykins J; Kukla C; Barcos M; Bennett J; Browman G
    Blood; 1990 Dec; 76(11):2191-7. PubMed ID: 2257293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and prognostic significance of in vivo differentiation in acute myeloid leukemia.
    Raza A; Preisler H; Lampkin B; Lykins J; Kukla C; Gartside P; Sheikh Y; Yousuf N; White M; Barcos M
    Am J Hematol; 1993 Feb; 42(2):147-57. PubMed ID: 8438874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In situ cell cycle kinetics in bone marrow biopsies following sequential infusions of IUdR/BrdU in patients with hematopoietic malignancies.
    Raza A; Yousuf N; Bohkari SA; Sheikh Y; Akhtar S; Chughtai S; Umerani A; Mehdi SA; Miller MA; Masterson M
    Leuk Res; 1992; 16(3):299-306. PubMed ID: 1560677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-cycle characteristics - alterable determinants of remission duration in a study of 179 standard risk newly diagnosed patients with acute myeloid-leukemia.
    Raza A; Yousuf N; Bokhari S; Abbas A; Lampkin B; Pancoast J; Bismayer J; Siegrist C; Browman G; Bennett J; Goldberg J; Grunwald H; Larson R; Tricot G; Vogler R; Gartside P; Preisler H
    Int J Oncol; 1993 Feb; 2(2):301-7. PubMed ID: 21573555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell cycle kinetics in childhood acute leukemia studied with in vitro bromodeoxyuridine labeling, Ki67-reactivity, and flow cytometry.
    Tsurusawa M; Aoyama M; Saeki K; Fujimoto T
    Leukemia; 1995 Nov; 9(11):1921-5. PubMed ID: 7475284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of bromodeoxyuridine (BrdU) and anti-BrdU monoclonal antibody for the in vivo analysis of proliferative characteristics of human leukemia cells in bone marrows.
    Nakamura S; Takeda Y; Kanno M; Yoshida T; Ohtake S; Kobayashi K; Okabe Y; Matsuda T
    Oncology; 1991; 48(4):285-9. PubMed ID: 1716352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo cell cycle characteristics of pediatric leukemia patients.
    Masterson M; Lampkin B; Yousuf N; Sheikh Y; Raza A
    Exp Hematol; 1992 Nov; 20(10):1184-7. PubMed ID: 1426098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new method for studying cell cycle characteristics in ANLL using double-labeling with BrdU and 3HTdr.
    Raza A; Maheshwari Y; Yasin Z; Mandava N; Mayers G; Preisler HD
    Leuk Res; 1987; 11(12):1079-87. PubMed ID: 3320580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the rate of DNA synthesis in myeloblasts from peripheral blood and bone marrows of patients with acute nonlymphocytic leukemia.
    Raza A; Yasin Z; Grande C
    Exp Cell Res; 1988 May; 176(1):13-9. PubMed ID: 3371420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two double labeling techniques to measure cell cycle kinetics in myeloid leukemias.
    Yousuf N; Yanik GA; George BA; Masterson M; Mazewski CM; White LM; Miller MA; Lampkin BC; Raza A
    Anticancer Res; 1991; 11(3):1195-9. PubMed ID: 1888149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High expression of transforming growth factor-beta long cell cycle times and a unique clustering of S-phase cells in patients with acute promyelocytic leukemia.
    Raza A; Yousuf N; Abbas A; Umerani A; Mehdi A; Bokhari SA; Sheikh Y; Qadir K; Freeman J; Masterson M
    Blood; 1992 Feb; 79(4):1037-48. PubMed ID: 1737088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in cell cycle characteristics among patients with acute nonlymphocytic leukemia.
    Raza A; Maheshwari Y; Preisler HD
    Blood; 1987 Jun; 69(6):1647-53. PubMed ID: 3555651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. All-trans retinoic acid and low-dose cytosine arabinoside for the treatment of 'poor prognosis' acute myeloid leukemia.
    Venditti A; Stasi R; Del Poeta G; Buccisano F; Aronica G; Bruno A; Pisani F; Caravita T; Masi M; Tribalto M
    Leukemia; 1995 Jul; 9(7):1121-5. PubMed ID: 7630182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between the per cent of marrow cells in S phase and the outcome of remission-induction therapy for acute nonlymphocytic leukaemia.
    Preisler HD; Azarnia N; Raza A; Grunwald H; Vogler R; Browman G; Goldberg J; Chervenick P; Miller K; Brennan J
    Br J Haematol; 1984 Mar; 56(3):399-407. PubMed ID: 6582925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of relapsed acute myeloid leukemia using GM-CSF before intensive chemotherapy.
    Puntous M; Lacombe F; Dumain P; Marit G; Cony-Makhoul P; Belloc F; Boiron JM; Laurent G; Bernard P; Reiffers J
    Leuk Lymphoma; 1993 Dec; 12(1-2):95-102. PubMed ID: 8161939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
    Pituch-Noworolska A
    Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell cycle characteristics in myeloid leukemias.
    Raza A; Khan SP; Mehdi I; Imren S; Yasin Z; Preisler HD
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():26-9. PubMed ID: 2713557
    [No Abstract]   [Full Text] [Related]  

  • 19. Biological characteristics of newly diagnosed poor prognosis acute myelogenous leukemia.
    Raza A; Preisler HD; Li YQ; Larson RA; Goldberg J; Browman G; Bennett J; Grunwald H; Vogler R; Kukla C
    Am J Hematol; 1993 Apr; 42(4):359-66. PubMed ID: 8493986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic contrast-enhanced MR imaging measurement of vertebral bone marrow perfusion may be indicator of outcome of acute myeloid leukemia patients in remission.
    Chen BB; Hsu CY; Yu CW; Hou HA; Liu CY; Wei SY; Chou WC; Tien HF; Shih TT
    Radiology; 2011 Mar; 258(3):821-31. PubMed ID: 21212370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.